Skip to content

Efficacy and mechanism of MEBO in repairing type 2 diabetic foot ulcer

Efficacy and mechanism of MEBO in repairing type 2 diabetic foot ulcer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001353
Enrollment
Unknown
Registered
2025-07-09
Start date
2024-07-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic foot ulcer

Interventions

Experimental group:Routine debridement and dressing change+MEBO
Control group:Routine debridement and dressing change

Sponsors

Yantai Yuhuangding Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with type 2 diabetes mellitus with foot ulcers. 2. Age =18 years old. 3.Wagner is rated 2-4. 4. There is no obvious necrotic tissue on the wound or the necrotic tissue has been removed by debridement. 5. The infection has been controlled and the wound is in a stable stage. 6. The skin around the wound had no obvious signs of acute infection such as redness swelling and heat pain. 7. No obvious skin diseases such as eczema and dermatitis. 8. Good skin integrity no extensive damage or ulcers. 9. Informed consent for this study can support treatment and follow-up.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women. 2. Smoking years =20 years. 3. Drink more than 3 standard drinks per day or more frequently than 5 times per week. 4. It has developed gangrene and requires amputation. 5. Complicated with major organ dysfunction. 6. Impaired nutritional intake. 7. Other serious complications. 8. Ankle-brachial index < 0.7. 9. Allergic reaction to the ingredients used in this study. 10. Have recently (within 1 month) used other local therapeutic drugs (such as antibiotic ointment growth factor etc.) or received other wound treatment. 11. Inability to cooperate with treatment or follow-up.

Design outcomes

Primary

MeasureTime frame
Wound healing rate;

Secondary

MeasureTime frame
Wound healing time;Evaluation of disease treatment efficacy;Macrophage mannose receptor(CD206);T lymphocyte activation antigen(CD86);Wound closure index;Local symptom score;Arginase 1(Arg-1);a-smooth muscle actin(a-SMA);Wound infection rate;Pain Visual Analogue Scale;inducible nitric-oxide synthse(iNOS);Platelet endothelial cell adhesion molecule(CD31);

Countries

China

Contacts

Public ContactXiaorui Jiang

Yuhuangding Hospital Yantai City Shandong Province

Jiang_xr007@163.com18653528603

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026